Common TitleSHIELD
Official Title A Pilot Study of Highly Active Antiretroviral Therapy Using Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Antiretroviral Naive HIV-Infected Subjects
Phase Phase IV
ClinicalTrials.gov NCT00740064
Treatments
Raltegravir
Raltegravir
Tradename:IsentressOther Names:RALClass:Integrase Inhibitors (INSTI)Categories Treatment-Naive
Funding
Non-IndustryDenver Infectious Disease Consultants, PLLC
References
- Young B, Vanig T, DeJesus E, et al. 96-week results of a pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: the SHIELD trial. HIV Clin Trials. 2011;12:228-33.
- Young B, Vanig T, Dejesus E, et al. A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trial. HIV Clin Trials. 2010;11:260-9.